About: Convalescent Plasma for COVID-19. A randomized clinical trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Convalescent Plasma for COVID-19. A randomized clinical trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Convalescent Plasma for COVID-19. A randomized clinical trial
Creator	Koopmans, Marion Haagmans, Bart Okba, Nisreen Den Hollander, Jan Hassing, Robert-Jan Katsikis, Peter Rijnders, Bart Rokx, Casper Swaneveld, Francis Van Der Eerden, Menno Ammerlaan, Heidi Bos, Jeannet Dofferhoff, Anthonius Geurtsvankessel, Corinne Gharbharan, Arvind Hofwegen, Henk Jordans, Carlijn Karim, Faiz Koster, Adrianus Ludwig, Inge Miedema, Jelle Mollema, Femke Mueller, Yvonne Papageorgiou, Grigorios Stalenhoef -Schukken, Janneke Steijaert, Monique Te Boekhorst, Peter Van Leeuwen -Segarceanu, Elena Van Pottelberge, Geert Vlasveld, Imro
Source	MedRxiv
abstract	Background After recovery from COVID-19, most patients have anti-SARS-CoV-2 neutralizing antibodies. Their convalescent plasma could be an inexpensive and widely available treatment for COVID-19. Methods The Convalescent-plasma-for-COVID (ConCOVID) study was a randomized trial comparing convalescent plasma with standard of care therapy in patients hospitalized for COVID-19 in the Netherlands. Patients were randomized 1:1 and received 300ml of plasma with anti-SARS-CoV-2 neutralizing antibody titers of at least 1:80. The primary endpoint was day-60 mortality and key secondary endpoints were hospital stay and WHO 8-point disease severity scale improvement on day 15. Results The trial was halted prematurely after 86 patients were enrolled. Although symptomatic for only 10 days (IQR 6-15) at the time of inclusion, 53 of 66 patients tested had anti-SARS-CoV-2 antibodies at baseline. A SARS-CoV-2 plaque reduction neutralization test showed neutralizing antibodies in 44 of the 56 (79%) patients tested with median titers comparable to the 115 donors (1:160 vs 1:160, p=0.40). These observations caused concerns about the potential benefit of convalescent plasma in the study population and after discussion with the data safety monitoring board, the study was discontinued. No difference in mortality (p=0.95), hospital stay (p=0.68) or day-15 disease severity (p=0.58) was observed between plasma treated patients and patients on standard of care. Conclusion Most COVID-19 patients already have high neutralizing antibody titers at hospital admission. Screening for antibodies and prioritizing convalescent plasma to risk groups with recent symptom onset will be key to identify patients that may benefit from convalescent plasma. Clinicaltrials.gov: NCT04342182
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.1101/2020.07.01.20139857
has license	medrxiv
sha1sum (hex)	4c41687efb1f3fffbe81391d5911c552f23f2782
schema:url	https://doi.org/10.1101/2020.07.01.20139857
resource representing a document's title	Convalescent Plasma for COVID-19. A randomized clinical trial
resource representing a document's body	covid:4c41687efb1f3fffbe81391d5911c552f23f2782#body_text
is schema:about of	named entity 'collection' named entity 'Blood' named entity 'Erasmus MC' named entity 'application' named entity 'helping' named entity 'financially' named entity 'free' named entity 'programming' named entity 'medical students' named entity 'COVID-19' named entity 'Netherlands' named entity 'data safety monitoring board' named entity 'randomized clinical trial' named entity 'Convalescent Plasma' named entity 'The members' named entity 'plasma' named entity 'peer review' named entity 'coronavirus infections' named entity 'WHO' named entity 'antibodies' named entity 'ribavirin' named entity 'primary endpoint' named entity 'Erasmus University Medical Center' named entity 'antiviral effect' named entity 'titer' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'COVID-19 disease' named entity 'SARS-CoV-2' named entity 'meta-analysis' named entity 'study population' named entity 'antibodies' named entity 'Europe' named entity 'virus' named entity 'convalescent plasma' named entity 'plasma' named entity 'ritonavir' named entity 'convalescent plasma' named entity 'gold standard' named entity 'medRxiv' named entity 'convalescent plasma' named entity 'MERS outbreaks' named entity 'Netherlands' named entity 'autologous' named entity 'preprint' named entity 'CRP' named entity 'virus' named entity 'Serum' named entity 'antiviral effect' named entity 'preprint' named entity 'peer review' named entity 'COVID' named entity 'IgM' named entity 'neutralizing antibodies' named entity 'GISAID' named entity 'aOR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software